Morningstar | ResMed is well-positioned for growth amid an underpenetrated sleep apnoea market.
ResMed targets a very large potential market opportunity. The National Heart Blood and Lung Institute estimates that 12 million Americans suffer from sleep apnoea; according to ResMed, fewer than 4 million of these are diagnosed or treated for sleep apnoea each year. By expanding the pool of diagnosed and treated sleep apnoea patients, companies that target the disorder have much to gain. ResMed's strategy involves increasing awareness of the disorder among physicians and the general population. The company is also making testing for sleep apnoea simpler with home testing devices, which expands the company's reach to patients unwilling to be treated at sleep labs. Most importantly, ResMed aims to introduce new devices that make patients more comfortable and compliant during treatment, which should provide the company with a stream of recurring revenue.
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.